Physician profile
Ryan T Runyon
NPI 1932115938
$21,421.19
in general payments reported to CMS, 2019-2025
35 companies · $2,010 in 2025
The $2,010 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,539 · 2020: $5,812 · 2021: $2,577 · 2022: $1,809 · 2023: $1,900 · 2024: $1,773 · 2025: $2,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,684.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $7,275.41 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $2,481.54 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,371.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,345.73 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Kowa Pharmaceuticals America, INC. | $1,214.55 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Amgen INC. | $1,202.70 | 2019-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $915.79 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $912.96 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $790.84 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $719.88 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Abbvie INC. | $638.12 | 2019-2025 | Ubrelvy |
| Pfizer INC. | $551.44 | 2019-2025 | |
| Abbott Laboratories | $338.53 | 2022-2025 | Freestyle Libre 2 |
| Esperion Therapeutics, INC. | $294.29 | 2021-2025 | Nexletol |
| Exact Sciences Corporation | $182.35 | 2023-2025 | Cologuard Collection Kit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $142.71 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $112.41 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $111.88 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $109.93 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $105.22 | 2019-2021 | |
| Eisai INC. | $92.05 | 2020-2022 | |
| Allergan, INC. | $86.79 | 2019-2020 | |
| Boston Scientific Corporation | $72.65 | 2024 | Ingevity Mri |
| E.R. Squibb & Sons, L.L.C. | $59.78 | 2019-2022 | |
| Shield Therapeutics INC | $46.71 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $42.60 | 2021 | |
| Dexcom, INC. | $39.76 | 2024-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $34.87 | 2024 | Gvoke Hypopen |
| Genentech USA, INC. | $22.14 | 2021 | |
| Axonics, INC. | $21.63 | 2023 | Axonics |
| Biomerieux INC | $21.00 | 2025 | Biofire Spotfire Control Station |
| Phathom Pharmaceuticals, INC. | $16.21 | 2024 | Voquezna |
| Tris Pharma INC | $15.95 | 2021 | |
| Medtronic USA, INC. | $15.89 | 2019 | |
| Insulet Corporation | $15.47 | 2025 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Runyon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.